Management of Seborrhea in Patients Taking Tofacitinib

Initial Assessment and Management

• The European League Against Rheumatism recommends ruling out infectious causes first, as urinary tract infections and other serious infections are the most common complications of tofacitinib therapy 1
• The American Gastroenterological Association suggests evaluating for herpes zoster, which can present with skin manifestations and occurs at significantly elevated rates in tofacitinib-treated patients 1
• The American College of Gastroenterology advises considering alternative diagnoses including psoriasis, atopic dermatitis, or other inflammatory dermatoses that may have developed independently 4

Standard Seborrhea Treatment Without Tofacitinib Discontinuation

• The American Academy of Dermatology recommends initiating conventional seborrheic dermatitis therapy with topical antifungals, topical corticosteroids, or calcineurin inhibitors, and continuing tofacitinib unless there is clear evidence of a serious infection or other contraindication requiring temporary discontinuation 1
• The European Society for Medical Oncology suggests monitoring for treatment response over 2-4 weeks with standard dermatologic therapies 2

When to Consider Tofacitinib Modification

• The American College of Rheumatology advises temporarily holding tofacitinib only if suspected serious skin infection develops, herpes zoster is diagnosed, or new-onset severe skin reaction suggesting drug hypersensitivity occurs 1, 2
• The National Institute for Health and Care Excellence recommends dose adjustment considerations, including reducing tofacitinib to 5 mg once daily for patients with severe renal impairment (CrCl <30 mL/min) 1, 3

Critical Pitfalls to Avoid

• The Gut journal suggests not assuming seborrhea is caused by tofacitinib without considering that it may be a coincidental dermatologic condition or related to the underlying inflammatory disease being treated 4
• The Gastroenterology journal advises not discontinuing effective tofacitinib therapy for a mild, manageable skin condition like seborrhea when the medication is controlling serious inflammatory disease (ulcerative colitis, rheumatoid arthritis) 4, 5, 6

Monitoring Recommendations

• The Annals of the Rheumatic Diseases journal recommends continuing standard tofacitinib monitoring regardless of seborrhea, including complete blood count with differential every 3 months, comprehensive metabolic panel every 3 months, lipid panel at 12 weeks then annually, and clinical assessment for infections at each visit 1, 2, 3